Age reshapes selection on melanoma driver mutations.
Aging changes which melanoma mutations give cancer cells an advantage, suggesting doctors may need to adjust treatment strategies based on patient age.
Evolutionary analysis of 5,472 melanomas demonstrated that aging primarily alters the selective advantage of key driver mutations rather than simply increasing overall mutation rates, with BRAF V600E becoming significantly less advantageous while NRAS Q61 mutations gain advantage in older patients. These age-dependent changes in driver selection motivate age-conscious evaluation of BRAF-targeted therapies and biomarkers, with implications for clinical trial stratification and treatment sequencing in age-diverse melanoma populations.
What the study was
- Study design
- computational_genomic_analysis
- Category
- precision_oncology_genomic_medicine
- Maturity
- Validated
- Journal
- Science Advances
Why it surfaced
Genuinely novel finding in Science Advances: age-dependent driver mutation selection challenges universal application of BRAF-targeted therapy criteria; spans precision oncology and aging biology; large dataset of 5,472 melanomas.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.